Phathom Pharmaceuticals Inc
NASDAQ:PHAT

Watchlist Manager
Phathom Pharmaceuticals Inc Logo
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Watchlist
Price: 17.56 USD -0.57%
Market Cap: 1.2B USD

Wall Street
Price Targets

PHAT Price Targets Summary
Phathom Pharmaceuticals Inc

Wall Street analysts forecast PHAT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PHAT is 22.85 USD with a low forecast of 12.12 USD and a high forecast of 30.45 USD.

Lowest
Price Target
12.12 USD
31% Downside
Average
Price Target
22.85 USD
30% Upside
Highest
Price Target
30.45 USD
73% Upside
Phathom Pharmaceuticals Inc Competitors:
Price Targets
UCB
Ucb SA
11% Upside
600566
Hubei Jumpcan Pharmaceutical Co Ltd
22% Upside
JUBLPHARMA
Jubilant Pharmova Ltd
35% Upside
605507
Guobang Pharma Ltd
22% Upside
600276
Jiangsu Hengrui Pharmaceuticals Co Ltd
34% Upside
LINCOLN
Lincoln Pharmaceuticals Ltd
118% Upside
PFE
Pfizer Inc
17% Upside

Revenue
Forecast

Revenue Estimate
Phathom Pharmaceuticals Inc

The compound annual growth rate of Phathom Pharmaceuticals Inc's revenue for the next 4 years is 91%.

N/A
Past Growth
91%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Phathom Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat

Net Income
Forecast

Net Income Estimate
Phathom Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-47%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PHAT's stock price target?
Price Target
22.85 USD

According to Wall Street analysts, the average 1-year price target for PHAT is 22.85 USD with a low forecast of 12.12 USD and a high forecast of 30.45 USD.

What is Phathom Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
91%

The compound annual growth rate of Phathom Pharmaceuticals Inc's revenue for the next 4 years is 91%.

Back to Top